KALV
KalVista Pharmaceuticals, Inc. · Healthcare
Chief Development Officer Christopher Yea sold $137K of KalVista Pharmaceuticals, Inc.
Sold$136,586
$11.76Price
11,610Shares
−13%Stake
What KALV did after the filing
- The stock from Tue, May 21 close, $11.61
- +1.6%
- S&P 500, same days
- +4.7%
Measured over 30 trading days, to the Jul 5 close.
Traded Mon, May 20. Filed Tue, May 21, 1:55 PM ET, during the session. Returns use the May 21 close and the Jul 5 close. Not investment advice.